A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration
NCT ID: NCT00346957
Last Updated: 2012-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
128 participants
INTERVENTIONAL
1999-04-30
2003-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
NCT00299507
Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)
NCT00051129
Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD
NCT00065728
Treatment of Age-Related Macular Degeneration With Anecortave Acetate
NCT00211458
Anecortave Acetate Versus Placebo in AMD Patients Following PDT
NCT00346866
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Anecortave Acetate 30
Anecortave acetate 30 mg
0.5ml administered onto the sclera once every six months for 24 months
Anecortave Acetate 15
Anecortave Acetate 15 mg
0.5ml administered onto the sclera once every six months for 24 months
Anecortave Acetate 3
Anecortave Acetate 3 mg
0.5ml administered onto the sclera once every six months for 24 months
Anecortave Acetate Vehicle
Anecortave Acetate Vehicle
0.5ml administered onto the sclera once every six months for 24 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anecortave acetate 30 mg
0.5ml administered onto the sclera once every six months for 24 months
Anecortave Acetate 15 mg
0.5ml administered onto the sclera once every six months for 24 months
Anecortave Acetate 3 mg
0.5ml administered onto the sclera once every six months for 24 months
Anecortave Acetate Vehicle
0.5ml administered onto the sclera once every six months for 24 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alcon Research
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C-98-03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.